Validation of a Flow Cytometry Assay for Monoclonal Antibody Binding
Author Information
Author(s): Mercedes Cedeño-Arias, Javier Sánchez-Ramírez, Rancés Blanco-Santana, Enrique Rengifo-Calzado
Primary Institution: Center of Molecular Immunology, Havana, Cuba
Hypothesis
The study aims to validate a flow cytometry-based assay for evaluating the binding of nimotuzumab to cells over-expressing EGFR.
Conclusion
The flow cytometry assay for nimotuzumab binding was found to be robust, specific, and precise, making it suitable for quality control in therapeutic applications.
Supporting Evidence
- The assay demonstrated high specificity with ≥ 97% binding of nimotuzumab to the target cells.
- Robustness testing showed that only formaldehyde fixation significantly affected the assay results.
- The assay met precision criteria with RSD < 2% for intra-assay and inter-assay variability.
Takeaway
The researchers created a test to see how well a cancer drug sticks to its target, and they found it works really well.
Methodology
The assay was validated by examining robustness, specificity, repeatability, and intermediate precision using flow cytometry.
Limitations
The assay's robustness was affected by cell fixation with paraformaldehyde.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website